Alembic Pharma’s Q4FY22 Quarter Results
Alembic Pharma’s net revenues grew 9% YoY in Q4FY22.
- 02 May 2022
- Alembic Pharma’s consolidated revenues for the quarter ended December (Q4FY22) were up 11% quarter-on-quarter (QoQ). On a year-on-year (YoY) basis, it witnessed a growth of 9%.
- Its expenses for the quarter were up 27% QoQ and 37% YoY.
- While the company reported a 80% QoQ net profit decline, the same was down by 86% on a YoY basis.
- The earnings per share (EPS) of Alembic Pharma stood at 1.8 during Q4FY22.
Alembic Pharma’s Financial Statements for Q4FY22:
Total Income | 1,306 | 1,287 | 1,426 | 11% | 9% |
Total Expenses | 1,014 | 1,090 | 1,385 | 27% | 37% |
Profit before tax | 292 | 197 | 41 | -79% | -86% |
Tax | 54 | 32 | -2 | - | - |
Profit after tax | 251 | 176 | 35 | -80% | -86% |
Earnings per share | 12.8 | 9.0 | 1.8 |
Data Source: BSE, Company announcements
Want to keep a tab on Indian listed companies? Open an account and get daily stock research updates from Kotak Securities.
The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Open Demat Account
Open Demat Account